Diffuse large B-cell lymphoma
Conditions
Interventions
The Epenemin group:Epenamin was added to the first-line regimen
Sponsors
Department of Hematology Medicine, the First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients with newly diagnosed DLBCL. 2.Age: 18~80 years old. 3.No prior chemotherapy or radiation therapy. 4.At least one lesion that can be measured or evaluated. 5.Complete blood count, liver and kidney function were generally normal: white blood cell >=3×10^9/L, neutrophil count >=1.5×10^9/L, platelet count >=100×10^9/L; Serum creatinine =50 mL min; The total bilirubin level was 2 times the upper limit of normal, and the aspartate and alanine aminotransferase levels were 3 times the upper limit of normal. 6.Predicted survival of >=3 months.
Exclusion criteria
Exclusion criteria: 1.Patients with DLBCL with non-TP53 mutations 2.Systemic central nervous system involvement 3.Previous or concomitant malignancies, and any coexisting medical problems that may lead to poor adherence to the study protocol. 4.Does not meet the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete remission;Overall response rate;Overall survival;Duration of response;Disease-free survival;Event-free survival; | — |
Countries
China
Contacts
Public ContactXiaoqiong Tang
the First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed